TGFB1 and Schwartz-Jampel syndrome: The CD25+ CD4+ T cells were further analyzed for expression of TGF-β, and the LL 301 medium dose showed significantly increased percentages of splenic TGF-β+ CD25+ CD4+ T cells relative to PBS- or WT LL-treated SjS females (Fig. 4C, D).